SCHEMBL1019441

SCHEMBL1019441

Fc1cc(F)cc(C#Cc2ccc(OC3CN4CCC3CC4)nn2)c1

nearest known ligand 0.46

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.46
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
LSS P48449 1/20 0.35
TLR7 Q9NYK1 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019582 0.90 GRM5 (0.44) CHRNA7CHRM2CHRM1
SCHEMBL1019786 0.90 CHRNA7 (0.44) CHRNA7CHRM2CHRM1LSS
SCHEMBL1018721 0.85 CHRNA7 (0.46) CHRNA7CHRM2CHRM1
SCHEMBL3084805 0.85 CHRNA7 (0.46) CHRNA7CHRM2CHRM1
SCHEMBL3088178 0.85 CHRNA7 (0.46) CHRNA7CHRM2CHRM1
SCHEMBL1019569 0.84 CHRNA7 (0.44) CHRNA7LSS
SCHEMBL1018979 0.84 CHRNA7 (0.44) CHRNA7CHRM2CHRM1TLR7
SCHEMBL1019629 0.84 CHRNA7 (0.45) CHRNA7CHRM2CHRM1LSS
SCHEMBL1018510 0.83 LSS (0.48) CHRNA7CHRM2CHRM1LSS
SCHEMBL1017804 0.83 CHRNA7 (0.44) CHRNA7CHRM2CHRM1LSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802616-B1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2011-01-12 EP claimed
US-7652010-B2 Azabicyclic aryl derivatives and their medical use NEUROSEARCH A/S (DK) 2010-01-26 US claimed
US-20070299082-A1 Novel Azabicyclic Aryl Derivatives and Their Medical Use ANIONA APS (DK) 2007-12-27 US claimed
EP-1802616-A1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2007-07-04 EP claimed
WO-2006040352-A1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-04-20 WO claimed
EP-1802616-B1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2011-01-12 EP disclosed
US-7652010-B2 Azabicyclic aryl derivatives and their medical use NEUROSEARCH A/S (DK) 2010-01-26 US disclosed
US-20070299082-A1 Novel Azabicyclic Aryl Derivatives and Their Medical Use ANIONA APS (DK) 2007-12-27 US disclosed
EP-1802616-A1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2007-07-04 EP disclosed
WO-2006040352-A1 NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299082-A1 Novel Azabicyclic Aryl Derivatives and Their Medical Use CHRNA6, CHRNA10, CHRNA5 CHRNA7 6/4885CHRM2 19/4885CHRM1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.